{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:48:21Z","timestamp":1789015701134,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whilst autologous stem cell transplantation (auto\u2010SCT) is considered standard of care for relapsed\/refractory classical Hodgkin lymphoma, the role of auto\u2010SCT in nodular lymphocyte\u2010predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto\u2010SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed\/refractory NLPHL who underwent first auto\u2010SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13\u201358), and the median number of prior treatment lines was 2 (range 1\u20135), including rituximab in 63% of the patients. At auto\u2010SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy\u2010two percent of the patients received BEAM as high\u2010dose therapy. With a median follow\u2010up of 56 months (range 3\u2013105), 5\u2010year progression\u2010free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto\u2010SCT (vs PR, <jats:italic>P<\/jats:italic>\u2009=\u2009.049) for OS. Auto\u2010SCT in patients with relapsed\/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long\u2010term survival independent of the time interval between diagnosis and transplant.<\/jats:p>","DOI":"10.1002\/ajh.24927","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T08:36:46Z","timestamp":1507019806000},"page":"40-46","source":"Crossref","is-referenced-by-count":27,"title":["High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte\u2010predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation\u2010lymphoma working party"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-0944","authenticated-orcid":false,"given":"Saad","family":"Akhtar","sequence":"first","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"},{"name":"Oncology Center, King Faisal Specialist Hospital and Research Center Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Finel","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Nemet","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fuhrmann","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveria","family":"Capria","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Malladi","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Moraleda","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meissner","sequence":"additional","affiliation":[{"name":"Medicine V, University of Heidelberg  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Lymphoma Working Party, EBMT Paris France"},{"name":"Medicine V, University of Heidelberg  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-008-9043-y"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200310000-00007"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi323"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541078"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0567"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-332"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123528"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.88"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3061.3061","article-title":"High\u2010dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin's disease","volume":"108","author":"Bierman P","year":"2006","journal-title":"Blood."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.03.008"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14567"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq063"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24819"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.006"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.273"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu440"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.005"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.286"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V128.22.922.922","article-title":"Relapsed Nodular Lymphocyte\u2010Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)","volume":"128","author":"Eichenauer DA","year":"2016","journal-title":"Blood."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24927","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:14:45Z","timestamp":1695539685000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/ajh.24927"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24927","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}